Novartis Eye Drug Requires Fewer Injections Than Regeneron Rival

Source: Reuters

Jun 20, 2017

Novartis said that trials showed its RTH258 drug would not need to be injected as frequently as a Regeneron rival for treating neovascular age-related macular degeneration (nAMD). nAMD is a leading cause of vision lost for people over 65-years old.

RTH258, also known as brolucizumab, worked as well as Regeneron's Eylea, with more than half of patients needing doses every 12 weeks, four weeks longer than Eyelea patients.

According to Novartis, the results have exceeded its expectations and hopes to file in 2018. Novartis also expects annual sales to exceed $1 billion.


Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments